Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03840161 · ClinicalTrials.gov registry record
Use of CoG by Patients With Diabetes Mellitus
A clinical trial, sponsored by Sciema UG.
- Completed
- Registry status
- 40
- Enrollment target
NCT03840161: Completed study, sponsored by Sciema UG.
NCT03840161 is a clinical trial that has completed, run by Sciema UG. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03840161 has completed, sponsored by Sciema UG.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The CNOGA Combo Glucometer (CoG) employs an invasive glucose meter using blood glucose teststrips and requiering a capillary blood sample obtained from a fingerstick and in addition, a non-invasive optical component for prediction of tissue glucose at the fingertip. In this study, participants will use both devices during meal tests and also at home during routine care. The results from the device will be compared to a standard reference method and will be used to determine the accuracy of the two device components.
Primary Outcome
Comparison of non-invasive CoG device measurements (tissue glucose in mg/dL) with the results of a standard laboratory reference method (YSI glucose analyzer, blood glucose in mg/dL) by consensus-error grid analysis
Interventions
- DEVICE non-invasive tissue glucose prediction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-07-16 |
| Est. Completion | 2019-03-31 |
What the finished NCT03840161 record still lists
NCT03840161 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which non-invasive tissue glucose prediction is the first listed.
NCT03840161 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03840161 about?
NCT03840161 is a clinical study titled "Use of CoG by Patients With Diabetes Mellitus". The CNOGA Combo Glucometer (CoG) employs an invasive glucose meter using blood glucose teststrips and requiering a capillary blood sample obtained from a fingerstick and in addition, a non-invasive optical component for prediction of tissue glucose at the fingertip. In this study, participants will ...
What is the current status of trial NCT03840161?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2018-07-16. Estimated completion is 2019-03-31.
What interventions are being tested in trial NCT03840161?
The interventions under investigation include: non-invasive tissue glucose prediction (DEVICE).
Who is sponsoring clinical trial NCT03840161?
This trial is sponsored by Sciema UG, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI